Acute Myeloid Leukemia Research Today is a free monthly online journal that collates and summarizes the latest research about Acute Myeloid Leukemia, including details on aml, symptoms, treatment, information.

Volume 1 (2004), Issue 4 (November)

1. Identical reconstitution after bone marrow transplantation in twins who received fresh and cryopreserved grafts harvested at the same time from their older brother.
   Clin Transplant, 18(6): 743-7. [Abstract] [Full-text]
2. Signal transduction of c-Kit receptor tyrosine kinase in CHRF myeloid leukemia cells.
   J Cancer Res Clin Oncol, 130(12): 711-8. [Abstract] [Full-text]
3. Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome.
   Cancer Res, 64(21): 8101-8. [Abstract] [Full-text]
4. The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia.
   Cancer Res, 64(21): 7927-35. [Abstract] [Full-text]
5. The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro.
   Eur J Haematol, 73(6): 418-26. [Abstract] [Full-text]
6. Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants.
   Ann Hematol, 83(12): 745-50. [Abstract] [Full-text]
7. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.
   Blood, 104(10): 3078-85. [Abstract] [Full-text]
8. Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia.
   Blood, 104(10): 3058-63. [Abstract] [Full-text]
9. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation.
   Blood Cells Mol Dis, 33(3): 261-6. [Abstract] [Full-text]
10. Canadian multicenter pilot trial of haploidentical donor transplantation.
    Blood Cells Mol Dis, 33(3): 222-6. [Abstract] [Full-text]
11. Alloreactive natural killer cells in mismatched hematopoietic stem cell transplantation.
    Blood Cells Mol Dis, 33(3): 216-21. [Abstract] [Full-text]
12. Several chromosomes involved in translocations with chromosome 5 shown with fluorescence in situ hybridization in patients with malignant myeloid disorders.
    Cancer Genet Cytogenet, 155(1): 74-8. [Abstract] [Full-text]
13. Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization.
    Cancer Genet Cytogenet, 155(1): 47-56. [Abstract] [Full-text]
14. Identification of B-cell translocation gene 1 as a biomarker for monitoring the remission of acute myeloid leukemia.
    Proteomics, 4(11): 3456-63. [Abstract] [Full-text]
15. Relative contributions of enzyme cytochemistry and flow cytometric immunophenotyping to the evaluation of acute myeloid leukemias with a monocytic component and of flow cytometric immunophenotyping to the evaluation of absolute monocytoses.
    Am J Clin Pathol, 122(6): 865-74. [Abstract] [Full-text]
16. An in vitro study on the mechanisms of coagulation activation in acute myelogenous leukemia (AML): role of tissue factor regulation by cytotoxic drugs and GM-CSF.
    Thromb Haemost, 92(5): 1136-46. [Abstract] [Full-text]
17. Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older.
    Leuk Res, 29(1): 53-7. [Abstract] [Full-text]
18. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia.
    Cancer Res, 64(22): 8443-50. [Abstract] [Full-text]
19. Transplantation of haploidentically mismatched stem cells for the treatment of malignant diseases.
    Springer Semin Immunopathol, 26(1): 155-68. [Abstract] [Full-text]
20. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.
    Blood, 104(12): 3754-7. [Abstract] [Full-text]
21. Gene expression profiling of pediatric acute myelogenous leukemia.
    Blood, 104(12): 3679-87. [Abstract] [Full-text]
22. Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo.
    Leukemia, 18(12): 1951-63. [Abstract] [Full-text]
23. In vitro selective suppression of feline myeloid colony formation is attributable to molecularly cloned strain of feline leukemia virus with unique long terminal repeat.
    Res Vet Sci, 78(2): 151-4. [Abstract] [Full-text]
24. The DEK protein--an abundant and ubiquitous constituent of mammalian chromatin.
    Gene, 343(1): 1-9. [Abstract] [Full-text]
25. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis.
    Thromb Res, 115(1): 59-64. [Abstract] [Full-text]
26. Successful umbilical cord blood transplantation for Fanconi anemia using preimplantation genetic diagnosis for HLA-matched donor.
    Am J Hematol, 77(4): 397-9. [Abstract] [Full-text]
27. Acute myeloid leukemia and Down syndrome evolution of modern therapy--state of the art review.
    Pediatr Blood Cancer, 44(1): 13-20. [Abstract] [Full-text]
28. Down syndrome, drug metabolism and chromosome 21.
    Pediatr Blood Cancer, 44(1): 33-9. [Abstract] [Full-text]
29. Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia.
    Pediatr Blood Cancer, 44(1): 63-9. [Abstract] [Full-text]
30. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
    J Clin Oncol, 22(23): 4816-22. [Abstract] [Full-text]
31. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
    Clin Cancer Res, 10(22): 7599-606. [Abstract] [Full-text]
32. Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells.
    J Cell Physiol, 202(2): 623-34. [Abstract] [Full-text]

© 2004-2008 Acute Myeloid Leukemia Research Today. All Rights Reserved.